CN115884775A - 用于治疗真菌感染的化合物及方法 - Google Patents

用于治疗真菌感染的化合物及方法 Download PDF

Info

Publication number
CN115884775A
CN115884775A CN202180050716.0A CN202180050716A CN115884775A CN 115884775 A CN115884775 A CN 115884775A CN 202180050716 A CN202180050716 A CN 202180050716A CN 115884775 A CN115884775 A CN 115884775A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
solvate
hydrate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180050716.0A
Other languages
English (en)
Chinese (zh)
Inventor
K·J·肖
H·施拉姆
M·R·霍齐斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basil Pharmaceuticals Allschwil International Ag
Original Assignee
Amplyx Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplyx Pharmaceutical Co filed Critical Amplyx Pharmaceutical Co
Publication of CN115884775A publication Critical patent/CN115884775A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180050716.0A 2020-06-17 2021-06-16 用于治疗真菌感染的化合物及方法 Pending CN115884775A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040450P 2020-06-17 2020-06-17
US63/040,450 2020-06-17
PCT/US2021/037578 WO2021257670A1 (en) 2020-06-17 2021-06-16 Compounds and methods for treating fungal infections

Publications (1)

Publication Number Publication Date
CN115884775A true CN115884775A (zh) 2023-03-31

Family

ID=79268375

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180050716.0A Pending CN115884775A (zh) 2020-06-17 2021-06-16 用于治疗真菌感染的化合物及方法

Country Status (12)

Country Link
US (1) US20230233586A1 (https=)
EP (1) EP4167998A4 (https=)
JP (1) JP2023530936A (https=)
KR (1) KR20230024375A (https=)
CN (1) CN115884775A (https=)
AU (1) AU2021293911B2 (https=)
BR (1) BR112022024988A2 (https=)
CA (1) CA3187268A1 (https=)
IL (1) IL299057A (https=)
MX (1) MX2022016179A (https=)
TW (1) TWI888580B (https=)
WO (1) WO2021257670A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010804A (es) 2020-03-04 2023-01-16 Amplyx Pharmaceuticals Inc Uso de compuestos en el tratamiento de infecciones fungicas.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060448A1 (ja) * 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
WO2020047510A1 (en) * 2018-08-31 2020-03-05 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections
CN115515599A (zh) * 2020-03-04 2022-12-23 安普利克斯制药公司 化合物在真菌感染的治疗中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
US8513287B2 (en) * 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US11819503B2 (en) * 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060448A1 (ja) * 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物
WO2020047510A1 (en) * 2018-08-31 2020-03-05 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections
CN115515599A (zh) * 2020-03-04 2022-12-23 安普利克斯制药公司 化合物在真菌感染的治疗中的用途

Also Published As

Publication number Publication date
CA3187268A1 (en) 2021-12-23
EP4167998A1 (en) 2023-04-26
JP2023530936A (ja) 2023-07-20
AU2021293911A1 (en) 2023-01-19
AU2021293911B2 (en) 2024-11-14
US20230233586A1 (en) 2023-07-27
KR20230024375A (ko) 2023-02-20
BR112022024988A2 (pt) 2022-12-27
WO2021257670A1 (en) 2021-12-23
MX2022016179A (es) 2023-04-20
EP4167998A4 (en) 2024-07-17
TW202214258A (zh) 2022-04-16
TWI888580B (zh) 2025-07-01
IL299057A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
US12521406B2 (en) Use of compounds in the treatment of fungal infections
JP7793681B2 (ja) 真菌感染症を処置するための化合物および方法
AU2024227501A1 (en) Antifungal agents with enhanced activity in acidic pH
TWI888580B (zh) 用於治療真菌感染之化合物及方法
RU2824066C1 (ru) Соединения и способы для лечения грибковых инфекций
HK40085944A (en) Compounds and methods for treating fungal infections
RU2805930C1 (ru) Использование соединений при лечении грибковых инфекций
HK40086224A (zh) 化合物在真菌感染的治疗中的用途
US20250302821A1 (en) Synergistic antifungal composition and method
TWI920017B (zh) 用於治療真菌感染之化合物及方法
KR20250090355A (ko) Iga 신병증 치료를 위한 엔도텔린 수용체 길항제 및 글루코코르티코이드의 조합
Riddell IV et al. Pharmacotherapy of micafungin: clinical review
CN105764506A (zh) 用于治疗与镰孢菌属真菌有关的肺炎的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085944

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20240129

Address after: Swiss Bonneville

Applicant after: Basil Pharmaceuticals Allschwil International AG

Country or region after: Switzerland

Address before: USA New York

Applicant before: AMPLYX Pharmaceutical Co.

Country or region before: U.S.A.

TA01 Transfer of patent application right